The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Update on the Drug Rediscovery Protocol: Expanded use of existing anticancer drugs in patients with a known molecular profile.
 
Jade Maxime van Berge Henegouwen
No Relationships to Disclose
 
Louisa Rose Hoes
No Relationships to Disclose
 
Hanneke van der Wijngaart
No Relationships to Disclose
 
Daphne Liselotte Van Der Velden
No Relationships to Disclose
 
Alwin Huitema
No Relationships to Disclose
 
Edwin P.J.G. Cuppen
No Relationships to Disclose
 
Elly J. Lugtenburg
No Relationships to Disclose
 
Filip Yves Francine Leon De Vos
Research Funding - Abbvie (Inst); BioClin Therapeutics (Inst); Novartis (Inst)
Expert Testimony - Bristol-Myers Squibb
 
Haiko Bloemendal
No Relationships to Disclose
 
Katrien Grunberg
No Relationships to Disclose
 
Henk M.W. Verheul
Consulting or Advisory Role - Glycostem (Inst)
 
Hans Gelderblom
Patents, Royalties, Other Intellectual Property - Amgen, Boehringer-Ingelheim, Pfizer, Novartis, Pharmamar, Daiichi, Five Prime (Inst)
Other Relationship - Daiichi Sankyo
 
Emile E. Voest
Consulting or Advisory Role - Biogeneration Ventures; InteRNA
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst)